Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate cancer confirmed by a biopsy, specifically a type called adenocarcinoma
- People whose cancer is at an early stage (T1c or T2), meaning it is contained within or just around the prostate
- People whose cancer has not been found in nearby lymph nodes, or where lymph nodes have not yet been assessed
- People whose cancer has not spread to other parts of the body, or where this has not yet been assessed
- People with a PSA blood test result below 20 ng/ml
- People whose cancer scores a 6 or 7 on the Gleason scale, which is a measure of how the cancer cells look under a microscope
- People who are able to sign a written consent form
Who may not be able to join:
- People under 18 years of age
- People whose cancer is at a more advanced stage (T3 or T4), meaning it has grown beyond the prostate
- People whose cancer has spread to nearby lymph nodes (N1)
- People whose cancer has spread to other parts of the body (M1)
- People with a PSA blood test result above 20 ng/ml
- People whose cancer scores 8, 9, or 10 on the Gleason scale
- People with a urinary symptom score (IPSS) above 20, or who are taking alpha-blocker medications (confirm with trial site)
- People who have previously had radiotherapy to the pelvic area
- People with a history of certain autoimmune connective tissue conditions, such as Lupus, Scleroderma, or Dermatomyositis
- People with a past history of Inflammatory Bowel Disease
- People who have prosthetic implants in both hips
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Andre-Guy Martin, CHU de Québec
Phone: 14186915264
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
GU toxicity analysis (CTCAE); GU toxicity analysis (CTCAE); GU toxicity analysis (CTCAE); GU toxicity analysis (CTCAE); GU toxicity analysis (CTCAE); GU toxicity analysis (CTCAE); GU toxicity analysis (CTCAE); GU toxicity analysis (CTCAE); GI toxicity analysis (CTCAE); GI toxicity analysis (CTCAE); GI toxicity analysis (CTCAE); GI toxicity analysis (CTCAE); GI toxicity analysis (CTCAE); GI toxicity analysis (CTCAE); GI toxicity analysis (CTCAE); GI toxicity analysis (CTCAE); urinary toxicity analysis (IPSS); urinary toxicity analysis (IPSS); urinary toxicity analysis (IPSS); urinary toxicity a...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.